ArticleHaematologica2011
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.
Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Pooled it
- Erythropoietin or darbepoetin for patients with cancer.The Cochrane database of systematic reviews · 2012Pooled it
- Oncology biosimilars: New developments and future directions.Cancer reports (Hoboken, N.J.) · 2022Review
- Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.Journal of clinical medicine · 2022Article
- ATR-FTIR spectroscopy and spectroscopic imaging for the analysis of biopharmaceuticals.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2020Review
- Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective.Global journal on quality and safety in healthcare · 2020Review
- Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation.Bone marrow transplantation · 2019Article
- Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.Pharmaceutical research · 2018Article
- Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Review
- Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.BioMed research international · 2018Article
- Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017Observational
- Article
- Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.Drug design, development and therapy · 2017Review
- Assessing the Immunogenicity of Biopharmaceuticals.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2016Review
- Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Transfusion · 2015Review
- Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury.BioMed research international · 2015Article
- Regulatory and clinical considerations for biosimilar oncology drugs.The Lancet. Oncology · 2014Review
- Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Biologics : targets & therapy · 2014Review
- Ethical issues and concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors.Blood transfusion = Trasfusione del sangue · 2012Article
- The advent of biosimilar therapies in rheumatology--"O brave new world".Nature reviews. Rheumatology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.